Navigation Links
Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
Date:3/27/2013

BURLINGTON, Mass., March 27, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish between current regimens utilized for the treatment and secondary prophylaxis of deep vein thrombosis (DVT)/pulmonary embolism (PE), as these regimens are initiated with use of a short-term injectable anticoagulant prior to long-term anticoagulation with warfarin. However, Bayer/Janssen's Xarelto and Bristol-Myers Squibb/Pfizer's Eliquis are expected to displace current therapies for the treatment and secondary prophylaxis of DVT/PE. Surveyed U.S. emergency room physicians indicate that Xarelto and Eliquis have competitive advantages in efficacy, safety and tolerability and delivery.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"We forecast that Xarelto will become the U.S. market leader in the treatment and secondary prophylaxis of DVT/PE, with a 22.4 percent patient share by 2021, closely followed by apixaban with 19.3 percent," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "This is due to these agents' impressive results in clinical trials, and the fact that oral therapy can be initiated straight away, removing the need to begin therapy with a fast-acting injectable anticoagulant."  

The DecisionBase 2013 report entitled Therapies with Improved Safety and Delivery Profiles Are Set to Overtake Enoxaparin and Warfarin as Leading Treatments of DVT/PE also finds that surveyed U.S. and European emergency room physicians agree that the incidence of VTE-related mortality is one of the attributes that most influences their decisions regarding prescribin
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
4. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
5. Sound Physicians Enters Agreement to Provide Hospitalist Services at Broward Health
6. U.S. Physicians Report Diabetic Nephropathy as the Renal Condition with the Highest Unmet Need for Treatment
7. Physicians Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021
8. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
9. Sunshine Act Survey: More Than 50% of Physicians Unprepared
10. iPad Altering Interaction between Pharma Sales Forces, Physicians, & Consumers
11. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Corporation (Nasdaq: IRIX ) today announced that management ... 23rd Annual OC Growth Stock Conference on Monday, March 14, ... March 13-16 at the Ritz Carlton Laguna Niguel in Dana ... live webcast on the Investor section of IRIDEX,s website at: ...
... Medical Devices strengthened its executive team with the appointment ... Joseph Lee, Xeridiem Medical Devices, President said, "I am ... Medical Devices as Vice-President Business Development, effective March 1, ... design and development services with a focus on sales ...
Cached Medicine Technology:Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development 2
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... The American Physical Therapy Association (APTA) is urging ... physical therapist, in light of a new federal survey ... nearly 12 percent of children use alternative medicine ... for treatment. Results of the 2007 survey of more ...
... 15, 2008 A program at Washington University School ... Hospital designed to increase awareness about sickle cell disease ... faith community led to a 60 percent increase in ... The program, called Sickle Cell Sabbath, was formally launched ...
... Statement , , VIRGINIA BEACH, ... AGP ) announced today that it filed a universal shelf ... Commission on December 15, 2008. The registration statement enables the ... debt, common stock, preferred stock and other securities at prices ...
... for Fighting AIDS joins PEPFAR, Nike Foundation, Coca-Cola Africa Foundation ... , NAIROBI, Kenya, Dec. 15 ... in Nairobi will rely on Rotarians for Fighting AIDS (RFFA) ... and economic development opportunities. , , ...
... Dec. 15 Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced ... 31, 2008. , , Highlights of the quarter and ... Revenues increased 11% versus comparable quarter in the previous ... 31, 2007 , Year-to-date company has won 8 ...
... of the American,Association of Drilling Engineers (AADE) recently ... to advance cancer research. The funds will,be used ... surgeon,Eugene Kim. The research program is focused on ... neuroblastoma, a deadly pediatric cancer. , ...
Cached Medicine News:Health News:Physical therapy offers evidence-based solution to musculoskeletal pain 2Health News:Church effort sharply increases first-time African-American blood donors 2Health News:AMERIGROUP Files Shelf Registration Statement 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 2Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 4Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 5Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 6Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 7Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 8Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 9Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 10Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 11Health News:Drilling Engineers Donate $35,000 to Texas Children's Hospital 2
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: